Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy

Author(s): Xue-Hang Fu, Rong-Yan Guan, Zoufang Huang, Yun Li, Guang Lu, Wei-Wei Mou* and Jun Du*

Volume 19, Issue 3, 2024

Published on: 13 July, 2023

Page: [396 - 401] Pages: 6

DOI: 10.2174/1574892818666230619093300

Price: $65

Abstract

Background: As the second most prevalent hematologic malignancy, multiple myeloma (MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly involving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically heterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting clonal heterogeneity throughout all stages from monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to MM. Although significant progress has been made in the treatment of MM, leading to improved patient outcomes, concerns are arising regarding disease relapse due to the presence and selection of pre-existing resistant clones or selective pressure during therapy.

Case Presentation: We present a case of multiple myeloma (MM) in a female patient, who underwent an 8-year course of treatment, including chemotherapy, immunomodulators, hematopoietic stem cell transplantation, CD38 monoclonal antibody, and chimeric antigen receptor T-cell (CAR-T), and was recently diagnosed with concurrent progressive MM and acute myeloid leukemia (AML). This patient has witnessed the evolution of MM treatment paradigms.

Conclusion: In this course, disease relapses occurred twice, one of which was manifested by a light chain escape (LCE). Moreover, through the course of the disease in this patient, we review the process of clonal evolution that may be relevant.

« Previous Next »
[1]
Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15(12): e538-48.
[http://dx.doi.org/10.1016/S1470-2045(14)70442-5] [PMID: 25439696]
[2]
Aksenova AY, Zhuk AS, Lada AG, et al. Genome instability in multiple myeloma: facts and factors. Cancers 2021; 13(23): 5949.
[http://dx.doi.org/10.3390/cancers13235949] [PMID: 34885058]
[3]
Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 2017; 14(2): 100-13.
[http://dx.doi.org/10.1038/nrclinonc.2016.122] [PMID: 27531699]
[4]
Salomon-Perzyński A, Jamroziak K, Głodkowska-Mrówka E. Clonal evolution of multiple myeloma-clinical and diagnostic implications. Diagnostics 2021; 11(9): 1534.
[http://dx.doi.org/10.3390/diagnostics11091534] [PMID: 34573876]
[5]
Braggio E, Kortüm KM, Stewart AK. Snapshot: multiple myeloma. Cancer Cell 2015; 28(5): 678-678.e1.
[http://dx.doi.org/10.1016/j.ccell.2015.10.014] [PMID: 26555176]
[6]
Schjesvold F, Oriol A. Current and novel alkylators in multiple myeloma. Cancers 2021; 13(10): 2465.
[http://dx.doi.org/10.3390/cancers13102465] [PMID: 34070213]
[7]
Burwick N, Sharma S. Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 2019; 98(1): 19-28.
[http://dx.doi.org/10.1007/s00277-018-3465-8] [PMID: 30073393]
[8]
Giralt S, Costa LJ, Maloney D, et al. Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the blood and marrow transplant clinical trials network 0102 trial. Biol Blood Marrow Transplant 2020; 26(4): 798-804.
[http://dx.doi.org/10.1016/j.bbmt.2019.11.018] [PMID: 31756536]
[9]
Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers 2020; 12(2): 265.
[http://dx.doi.org/10.3390/cancers12020265] [PMID: 31979059]
[10]
Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 2017; 77(5): 505-20.
[http://dx.doi.org/10.1007/s40265-017-0689-1] [PMID: 28205024]
[11]
Overdijk MB, Jansen JHM, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcγ receptor-mediated cross-linking. J Immunol 2016; 197(3): 807-13.
[http://dx.doi.org/10.4049/jimmunol.1501351] [PMID: 27316683]
[12]
Ritchie D, Colonna M. Mechanisms of action and clinical development of elotuzumab. Clin Transl Sci 2018; 11(3): 261-6.
[http://dx.doi.org/10.1111/cts.12532] [PMID: 29272564]
[13]
Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ 2020; 370: m3176.
[http://dx.doi.org/10.1136/bmj.m3176] [PMID: 32958461]
[14]
Spencer A, Mollee P, Blacklock HA, et al. Real-world outcome for newly diagnosed patients with functional high-risk myeloma - a myeloma and related diseases registry analysis. Blood 2019; 134 (Suppl. 1): 269-9.
[http://dx.doi.org/10.1182/blood-2019-129431]
[15]
van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet 2021; 397(10272): 410-27.
[http://dx.doi.org/10.1016/S0140-6736(21)00135-5] [PMID: 33516340]
[16]
Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol 2017; 28(2): 228-45.
[http://dx.doi.org/10.1093/annonc/mdw606] [PMID: 27864218]
[17]
Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011; 365(23): 2241-2.
[http://dx.doi.org/10.1056/NEJMc1111010] [PMID: 22150057]
[18]
Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 2000; 65(2): 123-7.
[http://dx.doi.org/10.1034/j.1600-0609.2000.90218.x] [PMID: 10966173]
[19]
Rosenberg AS, Brunson A, Tuscano J, et al. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J 2021; 11(1): 5.
[http://dx.doi.org/10.1038/s41408-020-00400-4] [PMID: 33414400]
[20]
McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 2017; 35(29): 3279-89.
[http://dx.doi.org/10.1200/JCO.2017.72.6679] [PMID: 28742454]
[21]
Holstein SA, Suman VJ, McCarthy PL. Update on the role of lenalidomide in patients with multiple myeloma. Ther Adv Hematol 2018; 9(7): 175-90.
[http://dx.doi.org/10.1177/2040620718775629] [PMID: 30013765]
[22]
Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012; 366(19): 1782-91.
[http://dx.doi.org/10.1056/NEJMoa1114138] [PMID: 22571202]
[23]
Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012; 120(8): 1597-600.
[http://dx.doi.org/10.1182/blood-2012-04-421883] [PMID: 22674807]
[24]
Fenk R, Neubauer F, Bruns I, et al. Secondary primary malignancies in patients with multiple myeloma treated with highdose chemotherapy and autologous blood stem cell transplantation. Br J Haematol 2012; 156(5): 683-6.
[http://dx.doi.org/10.1111/j.1365-2141.2011.08905.x] [PMID: 22050384]
[25]
San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013; 31(4): 448-55.
[http://dx.doi.org/10.1200/JCO.2012.41.6180] [PMID: 23233713]
[26]
Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375(14): 1319-31.
[http://dx.doi.org/10.1056/NEJMoa1607751] [PMID: 27705267]
[27]
Thura Win Htut DPQ. Incidence of second primary malignancies and peripheral sensory neuropathy in patients with multiple myeloma receiving daratumumab containing regimen. Blood 2019; 134(S1): 5550.
[28]
Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood 2012; 120(5): 927-8.
[http://dx.doi.org/10.1182/blood-2012-06-430645] [PMID: 22859708]
[29]
Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014; 5(1): 2997.
[http://dx.doi.org/10.1038/ncomms3997] [PMID: 24429703]
[30]
Neuse CJ, Lomas OC, Schliemann C, et al. Genome instability in multiple myeloma. Leukemia 2020; 34(11): 2887-97.
[http://dx.doi.org/10.1038/s41375-020-0921-y] [PMID: 32651540]
[31]
Lloyd MC, Cunningham JJ, Bui MM, Gillies RJ, Brown JS, Gatenby RA. Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res 2016; 76(11): 3136-44.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-2962] [PMID: 27009166]
[32]
Suzuki K, Nishiwaki K, Yano S. Treatment strategies considering micro-environment and clonal evolution in multiple myeloma. Cancers 2021; 13(2): 215.
[http://dx.doi.org/10.3390/cancers13020215] [PMID: 33435539]
[33]
Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia 2019; 33(2): 313-8.
[http://dx.doi.org/10.1038/s41375-018-0339-y] [PMID: 30573778]
[34]
Caldini A, Nozzoli C, Terreni A, et al. New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation. Clinic Chem Lab Med (CCLM) 2016; 54(6): 991-5.
[http://dx.doi.org/10.1515/cclm-2015-0689] [PMID: 26581069]
[35]
Brioli A, Giles H, Pawlyn C, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood 2014; 123(22): 3414-9.
[http://dx.doi.org/10.1182/blood-2013-12-542662] [PMID: 24733348]
[36]
Kraj M, Kruk B, Endean K, Warzocha K, Budziszewska K, Dąbrowska M. Light chain escape in 3 cases: evidence of intraclonal heterogeneity in multiple myeloma from a single institution in Poland. Case Rep Hematol 2015; 2015: 1-5.
[http://dx.doi.org/10.1155/2015/809840] [PMID: 26881153]
[37]
Sridharan A, Schinke CD, Georgiev G, et al. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv 2019; 3(23): 3962-7.
[http://dx.doi.org/10.1182/bloodadvances.2019000731] [PMID: 31805192]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy